Xiaosa Li
Impact in
-
- Innovation and Socioeconomic Development
- Aging top 10%
Papers in
-
- RNA modifications and cancer 4
- CRISPR and Genetic Engineering 3
- RNA Research and Splicing 2
-
- Cancer, Lipids, and Metabolism 2
- Co-authors
- Jia Chen (3 shared papers)Bei Yang (3 shared papers)Xiaodong Fu (14 shared papers)Li Yang (2 shared papers)Jia Wei (2 shared papers)Ying Wang (2 shared papers)Xiao Wang (2 shared papers)Tommaso Simoncini (5 shared papers)
In The Last Decade
Xiaosa Li
20 papers receiving 883 citations
Xiaosa Li's Hit Papers
Peers
Comparison fields: 5 of 88
- Business and International Management 66
- Aging 28
- Molecular Biology 670
- Cancer Research 96
- Biochemistry 46
Countries citing papers authored by Xiaosa Li
This map shows the geographic impact of Xiaosa Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaosa Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaosa Li more than expected).
Fields of papers citing papers by Xiaosa Li
This network shows the impact of papers produced by Xiaosa Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaosa Li. The network helps show where Xiaosa Li may publish in the future.
Co-authors
The 25 scholars most cited alongside Xiaosa Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Base editing with a Cpf1–cytidine deaminase fusion Hit paper breakdown → | 2018 | 322 |
| 2 | 2022 | 102 | |
| 3 | 2018 | 53 | |
| 4 | 2017 | 52 | |
| 5 | 2014 | 50 | |
| 6 | 2017 | 48 | |
| 7 | 2020 | 40 | |
| 8 | 2016 | 39 | |
| 9 | 2019 | 34 | |
| 10 | 2013 | 34 | |
| 11 | 2018 | 33 | |
| 12 | 2024 | 19 | |
| 13 | 2017 | 16 | |
| 14 | 2019 | 10 | |
| 15 | 2017 | 10 | |
| 16 | 2021 | 8 | |
| 17 | 2024 | 6 | |
| 18 | 2024 | 5 | |
| 19 | 2024 | 4 | |
| 20 | 2023 | 3 |
About Xiaosa Li
Xiaosa Li is a scholar working on Molecular Biology, Cancer Research, Genetics, Biochemistry and Pulmonary and Respiratory Medicine, having authored 22 papers that have together received 888 indexed citations. Recurring topics across this work include RNA modifications and cancer (4 papers), CRISPR and Genetic Engineering (3 papers), Eicosanoids and Hypertension Pharmacology (3 papers), Nitric Oxide and Endothelin Effects (3 papers), Estrogen and related hormone effects (3 papers), Cancer, Lipids, and Metabolism (2 papers), Sulfur Compounds in Biology (2 papers) and RNA Research and Splicing (2 papers). The work is most often cited by research in Business and International Management (66 citations), Aging (28 citations), Molecular Biology (670 citations), Cancer Research (96 citations) and Biochemistry (46 citations). Xiaosa Li has collaborated with scholars based in China, Italy and Australia. Frequent co-authors include Jia Chen, Bei Yang, Xiaodong Fu, Li Yang, Jia Wei, Ying Wang, Xiao Wang, Tommaso Simoncini, Jing Wu and Zongyang Lu. Their work appears in journals such as Trends in Endocrinology and Metabolism, Theranostics, Vascular Pharmacology, Cellular & Molecular Biology Letters and Nature Communications.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.